

# Alessandro Pastore

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4129671/publications.pdf>

Version: 2024-02-01

34  
papers

4,812  
citations

304368

22  
h-index

476904

29  
g-index

34  
all docs

34  
docs citations

34  
times ranked

10298  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	9.4	110
2	PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN. <i>Cancer Discovery</i> , 2020, 10, 1742-1757.	7.7	55
3	Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma. <i>Cell Reports</i> , 2020, 31, 107522.	2.9	50
4	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. <i>Cancer Cell</i> , 2020, 38, 198-211.e8.	7.7	99
5	Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis. <i>Cancer Discovery</i> , 2019, 9, 1452-1467.	7.7	60
6	Somatic mutations and cell identity linked by Genotyping of Transcriptomes. <i>Nature</i> , 2019, 571, 355-360.	13.7	206
7	CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A. <i>Journal of Hematology and Oncology</i> , 2019, 12, 85.	6.9	7
8	Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. <i>Nature</i> , 2019, 569, 576-580.	13.7	195
9	Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. <i>Nature Communications</i> , 2019, 10, 1874.	5.8	63
10	Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2019, 35, 369-384.e7.	7.7	238
11	Impact of age on clinical risk scores in follicular lymphoma. <i>Blood Advances</i> , 2019, 3, 1033-1038.	2.5	18
12	Lactose drives <i>Enterococcus</i> expansion to promote graft-versus-host disease. <i>Science</i> , 2019, 366, 1143-1149.	6.0	217
13	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. <i>Nature Medicine</i> , 2019, 25, 1839-1842.	15.2	122
14	Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. <i>Nature</i> , 2019, 574, 273-277.	13.7	149
15	PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN. <i>Blood</i> , 2019, 134, 473-473.	0.6	4
16	Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma. <i>Blood</i> , 2019, 134, 657-657.	0.6	0
17	Expression of mutant Asx11 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. <i>Journal of Experimental Medicine</i> , 2018, 215, 1729-1747.	4.2	113
18	Impact of age on genetics and treatment efficacy in follicular lymphoma. <i>Haematologica</i> , 2018, 103, e364-e367.	1.7	10

#	ARTICLE	IF	CITATIONS
19	KMT2C mediates the estrogen dependence of breast cancer through regulation of ER $\pm$ enhancer function. <i>Oncogene</i> , 2018, 37, 4692-4710.	2.6	102
20	Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. <i>Cancer Cell</i> , 2018, 34, 225-241.e8.	7.7	162
21	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. <i>Blood</i> , 2018, 132, 1695-1702.	0.6	49
22	Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms. <i>Blood</i> , 2018, 132, 49-49.	0.6	10
23	Targeting MYC-Driven B-Cell Lymphoma By Inhibition of the Histone Methyltransferase DOT1L. <i>Blood</i> , 2018, 132, 2839-2839.	0.6	2
24	High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations. <i>Blood</i> , 2018, 132, 541-541.	0.6	1
25	Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial. <i>Blood</i> , 2018, 132, 4096-4096.	0.6	0
26	Therapeutic Targeting of an RNA Splicing Factor Network for the Treatment of Myeloid Neoplasms. <i>Blood</i> , 2018, 132, 427-427.	0.6	0
27	Multimodal Single-Cell Profiling Defines the Epigenetic Determinants of Chronic Lymphocytic Leukemia Evolution. <i>Blood</i> , 2018, 132, 1312-1312.	0.6	0
28	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 1018-1029.	7.7	302
29	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. <i>Nature Communications</i> , 2017, 8, 15429.	5.8	55
30	A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. <i>Nature</i> , 2017, 549, 389-393.	13.7	144
31	HIGHER MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA. <i>Hematological Oncology</i> , 2017, 35, 97-98.	0.8	0
32	Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. <i>Nature Medicine</i> , 2016, 22, 672-678.	15.2	301
33	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. <i>Lancet Oncology</i> , The, 2015, 16, 1111-1122.	5.1	483
34	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <i>Cell</i> , 2015, 163, 506-519.	13.5	1,485